Home › Research › Treatments
Recomendaciones de uso de donanemab
Paulina Elizabeth Bombón-Albán, Tatiana Gabriela Aldaz-López. Acta neurológica colombiana, 2026-05-06
Topic: Risk, prevention and care in population studies
La carta al editor presenta recomendaciones actualizadas para el uso de donanemab en la enfermedad de Alzheimer (EA), basadas en su papel dentro de la hipótesis de la cascada amiloide. Este anticuerpo monoclonal IgG1 se dirige a formas específicas de β-amiloide y promueve su eliminación mediante mecanismos mediados por microglía. Se destacan los resultados de ensayos clínicos como TRAILBLAZER-ALZ, en los cuales donanemab demostró una reducción significativa de la carga de placas amiloides y una ralentización de la progresión clínica de la enfermedad en etapas tempranas. El texto analiza también aspectos de seguridad, especialmente las anomalías de imagen relacionadas con amiloide (ARIA), que presentan mayor incidencia en pacientes tratados, particularmente en portadores del genotipo APOE ε4 homocigoto. Esto subraya la necesidad de implementar cribado genético y monitorización con resonancia magnética. Se enfatiza que el tratamiento está indicado únicamente en pacientes con deterioro cognitivo leve o demencia leve, y no en fases avanzadas o en poblaciones sin evidencia suficiente de beneficio. Además, se resalta el papel clave de los biomarcadores para confirmar la patología amiloide y seleccionar candidatos adecuados. Finalmente, se recomienda una cuidadosa selección de pacientes y estrategias de seguimiento para optimizar la seguridad y eficacia del tratamiento.
Key findings
- El texto analiza también aspectos de seguridad, especialmente las anomalías de imagen relacionadas con amiloide (ARIA), que presentan mayor incidencia en pacientes tratados, particularmente en portadores del genotipo APOE ε4 homocigoto.
- Esto subraya la necesidad de implementar cribado genético y monitorización con resonancia magnética.
- Se enfatiza que el tratamiento está indicado únicamente en pacientes con deterioro cognitivo leve o demencia leve, y no en fases avanzadas o en poblaciones sin evidencia suficiente de beneficio.
- Además, se resalta el papel clave de los biomarcadores para confirmar la patología amiloide y seleccionar candidatos adecuados.
- Finalmente, se recomienda una cuidadosa selección de pacientes y estrategias de seguimiento para optimizar la seguridad y eficacia del tratamiento.
Why it matters
These recommendations state that donanemab is indicated only for patients with mild cognitive impairment or mild dementia, not advanced stages, and that biomarkers are needed to confirm amyloid pathology and select candidates. They highlight ARIA as a safety concern with higher incidence in treated patients, particularly APOE ε4 homozygotes, requiring genetic screening and MRI monitoring.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 27 of the 96 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Acta neurológica colombiana) |
| Journal's citation record | 0 / 4 | Acta neurológica colombiana: journal h-index 11 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Tatiana Gabriela Aldaz-López holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Universidad San Francisco de Quito: institution h-index 164 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 27 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 27 of the 96 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Bombón-Albán, P. E., & Aldaz-López, T. G. (2026). Recomendaciones de uso de donanemab. Acta neurológica colombiana. https://doi.org/10.22379/anc.1993
Vancouver
Bombón-Albán PE, Aldaz-López TG. Recomendaciones de uso de donanemab. Acta neurológica colombiana. 2026. doi:10.22379/anc.1993.
BibTeX
@article{bombonalban2026-ef1b4e53,
author = {Bombón-Albán, Paulina Elizabeth and Aldaz-López, Tatiana Gabriela},
title = {{Recomendaciones de uso de donanemab}},
journal = {Acta neurológica colombiana},
year = {2026},
doi = {10.22379/anc.1993},
url = {https://doi.org/10.22379/anc.1993}
}